A clinical study of sedative and analgesic effect of dexamethasone combined with esketamine or sufentanil in radiofrequency ablation of lung tumor

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100050021

Enrollment

Unknown

Registered

2021-08-16

Start date

2022-03-10

Completion date

Unknown

Last updated

2022-10-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

radiofrequency ablation of lung tumor

Interventions

experimental group:Esketamine + Dexmedetomidine

control group: Sufentanil + Dexmedetomidine

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Aged 18 to 75 years; 2. ASA classification is between I-II; 3. The number of tumors is less than or equal to 3; 4. The operation time is less than 2h; 5. BMI index (body mass index) does not exceed 30; 6. Able to sign the informed consent form independently.

Exclusion criteria

Exclusion criteria: 1. Known history of allergic reactions to the drugs planned for the study; 2. Long-term use of sedatives and pain relievers; 3. Severe ischemic heart disease, mental illness, chronic pain, pregnancy, seizures, increased intracranial pressure; 4. A history of acute upper respiratory tract infection in the past 2 weeks; 5. Coagulation disorders or the use of antiplatelet or anticoagulant drugs.

Design outcomes

Primary

Measure	Time frame
pain response score;	—

Secondary

Measure	Time frame
modified alertness/sedation score;postoperative nausea and vomiting;bispectral index;respiratory depression;	—

Countries

China

Contacts

Public ContactLin Zhonglan

Zhejiang Chinese Medical University

linzhonglan@163.com+86 15158655782

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 10, 2026